EXACT Therapeutics AS to present at the Annual International Symposium for Therapeutic Ultrasound (ISTU) Conference in Toronto
Real-time intravital imaging of the vascular effects induced by ACT® in a murine brain
OSLO/LONDON, 1st June 2022: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical-stage biopharmaceutical company with a mission to enhance the therapeutic efficacy of medicines through ultrasound-mediated drug delivery, today announces the presentation of preclinical results of Acoustic Cluster Therapy (ACT®) in a murine brain model, at the Annual International Symposium for Therapeutic Ultrasound (ISTU) Conference being held on 7th -10th June 2022 in Toronto, Canada.
The ISTU is a non-profit organization founded in 2001 to increase and diffuse the knowledge of therapeutic ultrasound to the scientific and medical community and facilitate the translation of therapeutic ultrasound techniques into the clinical area for the benefit of patients worldwide.
The work presented by EXACT-Tx at the ISTU demonstrates the possibility of using ACT® to help deliver therapeutics to the brain, addressing a significant unmet medical need with close to 98% of drugs in development unable to cross the blood-brain barrier (BBB).
Dr Masha Strømme, Executive Chair EXACT-Tx said: “These data sets have deepened our understanding of the mechanism behind ACT®-induced increased BBB permeability and enhanced accumulation of co-injected molecules, and also given us new insights on the spatial and temporal extravasation pattern induced by ACT®, important for understanding the mechanism of this therapeutic strategy for drug delivery to the brain.”
Presentation details are listed below:
Oral Presentation: Real-time intravital imaging of the vascular effects induced by Acoustic Cluster Therapy (ACT®) in a murine brain
Session: Scientific Session 8A - Organ Focus: Brain.
Date and Time: Friday 10th June at 10.30am
ENDS
For more information, please contact:
Masha Strømme, Executive Chair
Exact Therapeutics
Email: Masha@exact-tx.com
Dominic Moreland, CFO
EXACT Therapeutics
Email: Dominic@exact-tx.com
About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com
Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.